Implications of the tumor microenvironment on survival and disease response in follicular lymphoma

Current Opinion in Oncology

Volumn 22, Issue 5, 2010, Pages 424-430

  Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

follicular lymphoma; macrophages; T regulatory cells; tumor microenvironment

Indexed keywords

BIOLOGICAL MARKER; CD23 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

B CELL LYMPHOMA; BIOPSY; CANCER CELL; CANCER SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOCOMPETENT CELL; OUTCOME ASSESSMENT; OVARY FOLLICLE CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, FOLLICULAR; MACROPHAGES; PROGNOSIS; STROMAL CELLS; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 77955386082     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833d5938     Document Type: Review

References (35)

1. Gribben JG. How I treat indolent lymphoma. Blood 2007; 109:4617-4626.
2. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-147.
3. Cullen MH, Lister TA, Brearley RI, et al. Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer 1979; 44:645-651.
4. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426-2433.
5. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-1265.
6. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27:4555-4562.
7. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-2169.
8. Dave SS. Follicular lymphoma and the microenvironment. Blood 2008; 111:4427-4428.
9. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23:6358-6363.
10. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169-2174.
11. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24:5052-5059.
12. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350-5357.
13. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25:390-398.
14. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOE-LAMS FL-2000 trial. J Clin Oncol 2008; 26:440-446.
15. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56:4625-4629.
16. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anticancer therapy. Eur J Cancer 2006; 42:717-727.
17. Alvaro T, Lejeune M, Camacho FI, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91:1605-1612.
18. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin- vincristine-prednisone. Clin Cancer Res 2007; 13:5784-5789.
19. Goval JJ, Thielen C, Bourguignon C, et al. The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. Haematologica 2008; 93:1169-1177.
20. Leich E, Salaverria I, Bea S, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic altera tions. Blood 2009; 114:826-834
21. O'RiainC, O'SheaDM, Yang Y, et al. Array-based DNAmethylation profiling in follicular lymphoma. Leukemia 2009; 23:1858-1866.
22. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957-2964.
23. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94:70-77.
24. Sweetenham JW, Goldman B, Leblanc ML, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol. 2009 Oct 29.
25. Curiel TJ. Regulatory T-cell development: is Foxp3 the decider? Nat Med 2007; 13:250-253.
26. Hallam S, Escorcio-Correia M, Soper R, et al. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 2009; 219:143-152.
27. Hagemann T, Lawrence T, McNeish I, et al. 'Re-educating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205:1261-1268.
28. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427-2437.
29. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-1174.
30. Ai WZ, Hou JZ, Zeiser R, et al. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009; 124:239-244.
31. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114:4713-4720.
32. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009; 27:1470-1476.
33. Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16:637-650.
34. de Jong D, de Boer JP. Predicting transformation in follicular lymphoma. Leuk Lymphoma 2009; 50:1406-1411.
35. Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115:289-295